Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents

被引：4

作者：

He, Shipeng ^{[1
]}

Dong, Guoqiang ^{[2
]}

Wu, Shanchao ^{[2
]}

Fang, Kun ^{[1
]}

Miao, Zhenyuan ^{[2
]}

Wang, Wei ^{[1
,3
]}

Sheng, Chunquan ^{[2
]}

机构：

[1] East China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China

[2] Second Mil Med Univ, Sch Pharm, Dept Med Chem, 325 Guohe Rd, Shanghai 200433, Peoples R China

[3] Univ New Mexico, Dept Chem & Chem Biol, MSCO3 2060, Albuquerque, NM 87131 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2018年 / 61卷 / 16期

基金：

中国国家自然科学基金; 国家重点研发计划;

关键词：

PROTEIN-PROTEIN INTERACTION; SUBEROYLANILIDE HYDROXAMIC ACID; T-CELL LYMPHOMA; P53; PATHWAY; VALPROIC ACID; SOLID TUMORS; HUMAN CANCER; DESIGN; ACTIVATION; APOPTOSIS;

D O I：

10.1021/acs.jmedchem.8b0064

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

p53-Murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important targets in antitumor drug development. Inspired by the synergistic effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors were identified, which showed excellent activities against both targets. In particular, compound 14d was proven to be a potent and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms were validated in cancer cells. Compound 14d showed excellent in vivo antitumor potency in the A549 xenograft model, providing a promising lead compound for the development of novel antitumor agents. Also, this proof-of concept study offers a novel and efficient strategy for multitargeting antitumor drug discovery.

引用

页码：7245 / 7260

页数：16

共 62 条

[31] From magic bullets to designed multiple ligands [J].

Morphy, R ;

Kay, C ;

Rankovic, Z .

DRUG DISCOVERY TODAY, 2004, 9 (15) :641-651

[32] Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death [J].

Nome, RV ;

Bratland, Å ;

Harman, G ;

Fodstad, O ;

Andersson, Y ;

Ree, AH .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (08) :1231-1238

[33] ONCOPROTEIN MDM2 CONCEALS THE ACTIVATION DOMAIN OF TUMOR SUPPRESSOR-P53 [J].

OLINER, JD ;

PIETENPOL, JA ;

THIAGALINGAM, S ;

GVURIS, J ;

KINZLER, KW ;

VOGELSTEIN, B .

NATURE, 1993, 362 (6423) :857-860

[34] Synergistic effects of suberoylanilide hydroxamic acid combined with cispiatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells [J].

Ong, Pei-Shi ;

Wang, Xin-Qiao ;

Lin, Ha-Shu ;

Chan, Sui-Yung ;

Ho, Paul C. .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 40 (05) :1705-1713

[35] 3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition [J].

Patil, Vishal ;

Sodji, Quaovi H. ;

Kornacki, James R. ;

Mrksich, Milan ;

Oyelere, Adegboyega K. .

JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (09) :3492-3506

[36] DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells [J].

Pont, Lotte M. E. Berghauser ;

Naipal, Kishan ;

Kloezeman, Jenneke J. ;

Venkatesan, Subramanian ;

van den Bent, Martin ;

van Gent, Dik C. ;

Dirven, Clemens M. F. ;

Kanaar, Roland ;

Lamfers, Martine L. M. ;

Leenstra, Sieger .

CANCER LETTERS, 2015, 356 (02) :525-535

[37] The Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious [J].

Popowicz, Grzegorz M. ;

Doemling, Alexander ;

Holak, Tad A. .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2011, 50 (12) :2680-2688

[38] Reaction of aromatic aldehydes with ammonium acetate [J].

Proskurnina, MV ;

Lozinskaya, NA ;

Tkachenko, SE ;

Zefirov, NS .

RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, 2002, 38 (08) :1149-1153

[39] The role of histone deacetylases (HDACs) in human cancer [J].

Ropero, Santiago ;

Esteller, Manel .

MOLECULAR ONCOLOGY, 2007, 1 (01) :19-25

[40] Recent Advances in the Therapeutic Perspectives of Nutlin-3 [J].

Secchiero, Paola ;

Bosco, Raffaella ;

Celeghini, Claudio ;

Zauli, Giorgio .

CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (06) :569-577

← 1 2 3 4 5 6 7 →